SEARCH

SEARCH BY CITATION

References

  • 1
    Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994;9:76-83.
  • 2
    Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63:584-588.
  • 3
    Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249:1-5.
  • 4
    Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997;37:3509-3529.
  • 5
    Jackson RG, Owsley C. Visual dysfunction, neurodegenerative diseases and aging. Neurol Clin North Am 2003;21:709-728.
  • 6
    Harnois C, Di PT. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-2475.
  • 7
    Langheinrich T, Tebartz van Elst L, Lagreze WA, Bach M, Lucking CH, Greenlee NW. Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visual evoked potentials and psychophysics. Clin Neurophysiol 2000;11:66-74.
  • 8
    Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson's disease. Brain 1978;101:661-671.
  • 9
    Jindahra P, Hedges TR, Mendoza-Santiesteban CE, Plant GT. Optical coherence tomography of the retina: applications in neurology. Curr Opin Neurol 2010;23:16-23.
  • 10
    Ascaso FJ, Cabezon L, Quintanilla MA, Gutierrez L, Lopez-Anton R, Cristobal JA, Lobo A. Retinal nerve fiber layer thickness measured by optical coherence tomography in patients with schizophrenia: a short report. Eur J Psychiatr 2010;24:227-235.
  • 11
    Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vis Res 2004;44:2793-2797.
  • 12
    Moschos MM, Tagaris G, Markopoulos I, et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur J Ophthalmol 2011;21:24-29.
  • 13
    Altintas O, Iseri P, Ozkan B, Caglar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol 2008;1116:137-146.
  • 14
    Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol 2010;4:1427-1432.
  • 15
    Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009;116:1493-1501.
  • 16
    Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011;17:431-436.
  • 17
    Shrier EM, Adam CR, Spund B, Glazman S, Bodis-Wollner I. Interocular asymmetry of foveal thickness in Parkinson disease [serial online]. J Ophthalmol 2012;2012:728457.
  • 18
    Ederer F. Shall we count numbers of eyes or numbers of subjects? Arch Ophthalmol 1973;89:1-2.
  • 19
    Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130:1586-1595.
  • 20
    Henderson JM, Carpenter K, Cartwright H, Halliday GM. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 2000;123:1410-1421.
  • 21
    Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004;111:1219-1235.
  • 22
    Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
  • 23
    Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 1988;10:137-144.
  • 24
    Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 2013;28:715-724.
  • 25
    Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990;13:296-302.
  • 26
    Bodis-Wollner I, Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vision Res 1998;38:1479-1487.
  • 27
    Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol 1996;100:1-11.
  • 28
    Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009;127:737-741.
  • 29
    Cubo E, Tedejo RP, Rodriguez Mendez V, et al. Retina thickness in Parkinson's disease and essential tremor. Mov Disord 2010;25 2461-2462.
  • 30
    Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007;48:2285-2289.